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Trichomonas vaginalis infection is highly prevalent worldwide and is associated with poor birth outcomes and
enhanced human immunodeficiency virus transmission. Traditional detection methods rely on microscopic
examination of vaginal specimens (wet mount) and culture, which can be insensitive and time-consuming.
More than 3,000 women attending two sexually transmitted disease clinics were enrolled in this cross-sectional
study to evaluate urine-based PCR for detection of T. vaginalis using a combined reference standard of wet
mount and culture from vaginal swab. The prevalence of trichomoniasis in the population was 16.7% (502 of
3,009 women) using the reference standard. PCR with urine combined with agarose gel-based detection was
66.9% sensitive and 98.3% specific compared to the reference standard. Detection of PCR products using an
unlabeled enzyme-linked immunosorbent assay (ELISA) improved the sensitivity to 86.4%, but specificity fell
to 86.1%. Using a digoxigenin-labeled ELISA for detection of amplified T. vaginalis DNA from urine, the
sensitivity and specificity of the PCR improved to 90.8 and 93.4%, respectively, compared to wet mount or
culture from vaginal swabs. For clinical research settings in which vaginal specimens are not available and
culture conditions are not feasible, urine-based PCR-ELISA may be useful for the detection of trichomoniasis
in women.
The urogenital protozoan parasite Trichomonas vaginalis is
the most common nonviral sexually transmitted pathogen in
developing and industrialized countries (20, 21, 23). Infections
in women cause vaginitis, urethritis, and cervicitis (4, 22); are
associated with poor birth outcomes (3, 6, 17); and may en-
hance transmission of the human immunodeficiency virus (8,
10). Traditionally, diagnosis of trichomoniasis in women has
relied on microscopic examination of wet mount preparations
made directly from vaginal secretions. Although rapid and
inexpensive, this technique is relatively insensitive (26) and
requires collection of a vaginal sample. Microscopic examina-
tion of cultures is more sensitive but is time-consuming and
more expensive. Diagnosis by either wet mount or culture
depends heavily on skilled and experienced microscopists and
requires the presence and maintenance of viable, motile
trichomonads.
In recent years, urine-based molecular amplification detec-
tion assays for the bacterial sexually transmitted pathogens
Chlamydia trachomatis and Neisseria gonorrhoeae have proven
invaluable for diagnosis in routine patient care and for epide-
miological research (1, 19, 24). The increased sensitivity over
culture and antigen-based detection methods combined with
the use of a noninvasive specimen and simple collection and
storage parameters has led to the widespread use of these
assays. This has been particularly useful in field research set-
tings where urine is the only biological specimen available and
culture conditions cannot be achieved. Accordingly, we sought
to develop and validate a PCR-based assay with urine for the
detection of T. vaginalis.
Several PCR-based diagnostic assays for trichomoniasis us-
ing vaginal specimens (7, 12, 25) and urine (11, 13, 28) from
women have recently been described. Lawing et al. found that
PCR from vaginal swabs was equivalent to culture (11). In the
present report, we evaluated urine-based PCR using previously
described primers (9) combined with agarose gel-based and
enzyme-linked immunosorbant assay (ELISA) detection meth-
ods in a large-scale validation study. Estimates of sensitivity
and specificity of the urine-based amplification tests were de-
termined by comparison to a combined reference standard of
wet mount and culture-positive vaginal swab specimens.
MATERIALS AND METHODS
Study population. The cross-sectional study was conducted in the sexually
transmitted disease (STD) clinics of two county health departments in central
North Carolina. Women were enrolled between October 1998 and March 2000.
Eligible subjects were between the ages of 18 and 65, spoke English, and denied
use of oral or topical metronidazole during the 4 weeks prior to specimen
collection. Women not meeting these criteria and those who refused to partici-
pate in the study were excluded.
Three thousand nine women agreed to participate in the study. Urine speci-
mens were received for PCR testing from 2,930 women. The final study popu-
lation comprises 2,147 women for whom the time and temperature limits for
urine storage and transportation were maintained, as described below.
The study was approved by the Committee on the Protection of Human
Subjects and the Institutional Review Board of the University of North Carolina
at Chapel Hill.
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Clinical data and specimen collection. A medical history was recorded for all
subjects according to the standard of care in the STD clinics. The standardized
history form included questions on symptoms, past history of an STD, and sexual
risk behaviors. In addition, subjects were asked the timing of the last urinary void
prior to their clinic visit and frequency of douching. For this analysis, symptom-
atic women were defined as those with an abnormal vaginal discharge; subjects
without a reported or observed abnormal discharge were considered asymptom-
atic.
Routine specimens were obtained from subjects during standardized pelvic
examinations. Vaginal swabs were collected for wet mount microscopy and T.
vaginalis culture; endocervical swabs were obtained for Gram staining, N. gon-
orrhoeae cultures, and C. trachomatis LCR (Abbott Diagnostics, Abbott Park,
Ill.) or EIA (Wampole Laboratories, Cranbury, N.J.). After the physical exam-
ination, subjects were asked to provide up to 20 ml of first-void urine in marked,
sterile specimen containers. Patients were instructed not to pour excess urine
from the container if the 20-ml mark was exceeded. For PCR detection of T.
vaginalis, specimen collection, storage, transport, and time limits for processing
were based on parameters established for LCR detection of N. gonorrhoeae and
C. trachomatis from urine (Abbott Diagnostics). Thus, urine specimens were
stored at 4°C and transported on ice within 3 days of collection to the Microbi-
ology Core Laboratory at the University of North Carolina at Chapel Hill.
Wet mount microscopy and T. vaginalis culture. Immediately after collection,
vaginal swabs were placed in sterile tubes containing 0.5 ml of normal saline and
agitated. One drop of the saline mixture was placed on a glass slide with a
coverslip and examined at a magnification of 200. A positive result was defined
as the presence of one or more trichomonads with characteristic morphology and
motility. The InPouch TV culture system (Biomed, San Jose, Calif.) was imme-
diately inoculated with a second vaginal swab according to the manufacturer’s
instructions. Pouch cultures were examined microscopically on day 2 or 3 and
again on day 5 after inoculation. A positive result was defined as the presence of
motile trichomonads at any time; a negative result was defined as the absence of
motile trichomonads at all readings.
T. vaginalis PCR from urine. To prevent bias in interpretation, persons per-
forming PCR were unaware of wet mount and culture results until after ampli-
fication results were recorded. During development of the urine-based PCR
assay for T. vaginalis, several combinations of specimen preparation and ampli-
fied product detection methods were tested. Initially, urine was processed using
a proteinase K treatment method. One milliliter of first void urine was centri-
fuged at 15,000  g for 15 min. The pellet was resuspended in 0.5 ml of
phosphate-buffered saline (PBS), centrifuged again and the final pellet was
resuspended in 0.05 ml of sterile water. Proteinase K was added to a final
concentration of 0.04 mg/ml, the solution was incubated for 1 h at 56°C, and the
enzyme was inactivated for 10 min at 95°C. Prepared specimens were frozen at
20°C until PCR was performed, using 0.01 ml as the template. Reaction
products from specimens prepared in this way were detected by agarose gel
electrophoresis as previously described (8).
We tested a second specimen preparation technique using the Amplicor CT
Urine Specimen Prep kit (Roche Diagnostic Systems, Indianapolis, Ind.). One
milliliter of first void urine was processed according to the manufacturer’s in-
structions and frozen at 20°C until PCR was performed, using 0.05 ml as
template. Specimens prepared by this procedure performed as well as or better
than those prepared with the proteinase K treatment. Since the completion of
this study, Amplicor has modified the CT urine prep buffers and procedures. The
currently available kits perform equally well for trichomonas PCR; however, this
study was conducted entirely with the earlier version of the product. PCR
products from specimens prepared in this way were detected using one of the
ELISA methods described below.
Oligonucleotide primers TVK3 and TVK7 (9) were used for all PCRs. These
primers specifically amplify a 312-bp sequence from repetitive DNA in the T.
vaginalis genome. PCR with TVK3 and TVK7 is negative with human DNA,
other organisms found in the human genitourinary tract, and other Trichomonas
species (9). Amplification reactions contained 20 pmol of each primer; 0.2 mM
(each) dATP, dCTP, dGTP, and dTTP or dUTP; 2.5 U of Taq DNA polymerase
(Gibco BRL, Grand Island, N.Y.); and 4 mM MgCl2 in 1 PCR buffer (Gibco
BRL) in a final volume of 0.1 ml. AmpErase (uracil N-glycosylase; Applied
Biosystems, Foster City, Calif.) was included in PCRs for detection by ELISA,
and dUTP was substituted for dTTP in the reaction mixture. PCR consisted of an
initial 5-min incubation at 90°C followed by 35 cycles of denaturation at 90°C for
1 min, annealing at 60°C for 30 s, and extension at 72°C for 2 min. Purified T.
vaginalis DNA and sterile water were used as positive and negative controls,
respectively.
ELISA detection of PCR products. For the ELISA without label, Immulon 2
HB microtiter plates (Dynex Technologies, Chantilly, Va.) were coated (40
ng/well) with TVK probe (5 TTCATGTCCTCTCCAAGCGTA 3) in 1 M
ammonium acetate. Plates were incubated at 37°C for 10 to 20 h, washed five
times with phosphate-buffered saline containing 1 mM EDTA, and stored at 4°C
in sealed plastic bags containing a dessicant pouch for up to 4 weeks. PCR was
performed with 5-biotinylated TVK3 and TVK7 for use with this ELISA. Am-
plified products were detected using the Amplicor CT detection kit according to
the manufacturer’s instructions except that TVK probe-coated plates were sub-
stituted for the kit plates. In this procedure, a streptavidin-horseradish peroxi-
dase conjugate binds amplified targets captured by the probe, a colorimetric
substrate is added, and absorbance is measured at 450 nm. Samples and PCR
positive and negative controls were tested in duplicate on each plate. In addition,
a biotinylated oligonucleotide corresponding to the reverse complement of the
TVK probe (40 ng/well) was used as an ELISA positive control for each plate.
Tests were considered valid if the absorbances of ELISA and PCR positive
controls were 1.0 and those of PCR negative controls were 0.1. The limit of
detection for PCR combined with the unlabeled ELISA was between 1 and 10
organisms per PCR mixture prepared from urine. The average standard error on
a typical plate was 14.5% of the mean for duplicate determinations.
We tested a second ELISA method using PCR with TVK3 and digoxigenin
(DIG)-labeled TVK7 and biotinylated TVK probe (the TVK probe hybridizes to
the amplified DNA strand generated with the TVK7 primer). PCR products
were detected using the PCR ELISA DIG detection kit (Roche Diagnostic
Systems) according to the manufacturer’s instructions. In this procedure, micro-
titer plates are precoated with streptavidin, which binds amplified target-probe
complexes via the biotinylated TVK probe. The DIG-labeled target is recognized
by an anti-DIG antibody-enzyme conjugate, a colorimetric substrate is added,
and absorbance is measured at 405 nm. Samples and PCR positive and negative
controls were tested in duplicate along with a DIG-labeled oligonucleotide
corresponding to the reverse complement of the TVK probe as an ELISA
positive control for each plate. Tests were considered valid if the absorbances of
ELISA positive controls were 1.0, those of PCR positive controls were 2.0,
and those of PCR negative controls were 0.2. The limits of detection for PCR
combined with the DIG ELISA were two organisms per PCR mixture prepared
from phosphate-buffered saline suspensions and eight organisms per PCR mix-
ture prepared from urine. The average standard error on a typical plate was 3.0%
of the mean for duplicate determinations.
Data analysis. Data were entered into databases created and maintained in
Microsoft Excel 2000 and EpiInfo (version 6.04; Centers for Disease Control and
Prevention, Atlanta, Ga.). Clinical and laboratory data were double entered by
different study personnel. Discrepant records were resolved by review of chart
information. Data analysis was performed using SAS version 7 (SAS Institute,
Cary, N.C.) and STATA version 6.0 (Stata Corp., College Station, Tex.).
For evaluation of the performance of the PCR assays, the reference standard
was based on the combined results of wet mount microscopy and culture from
vaginal swabs. Presence of trichomoniasis was defined as the presence of motile
trichomonads by either test. Absence of trichomoniasis was defined as the ab-
sence of motile trichomonads by both tests. Estimates of the sensitivity and
specificity and 95% confidence intervals (CIs) were computed for each PCR
assay using standard methods. Nonparametric receiver-operating characteristic
(ROC) analysis was performed for the two PCR-ELISAs. Sensitivity and speci-
ficity of the PCR were calculated for every possible ELISA absorbance cutoff
value. Sensitivity was plotted against 1  specificity at each value to obtain the
ROC curve. The absorbance value corresponding to the upper leftmost point of
the ROC curve is the ELISA cutoff point that jointly optimizes sensitivity and
specificity.
T. vaginalis culture and wet mount are known to be imperfect tests. In partic-
ular, the sensitivity of these tests is recognized to be less than 1. As a result,
specificity estimates using wet mount or culture as the reference standard are
subject to reference test bias. We assessed the potential impact of this bias by
adjusting the estimates of specificity using the formula of Staquet et al. (27). We
assumed the sensitivity and specificity of the combined reference standard to be
0.70 and 1.0, respectively. This method also assumes the reference standard tests
and PCR are independent. Under the assumption that the specificity of the
reference standard is 1.0, the sensitivity estimates for the new tests are unbiased
(27).
RESULTS
Patient population. Of 4,015 women attending the two
county health department STD clinics invited to participate in
the study, 3,009 met the inclusion criteria. Only 2% of invited
women refused to participate in the study. The majority of
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included and excluded subjects comprised African-Americans.
Caucasians were the next most common in both groups. His-
panic women were more likely to be excluded, primarily due to
the English-language-only inclusion criterion.
Women presenting to the clinics were most likely to seek
medical attention because of symptoms, for STD screening, or
because they had partners who had been diagnosed with an
STD (Table 1). Twenty-three women (0.8% of the study pop-
ulation) reported a partner who had been diagnosed with T.
vaginalis infection. Sixty-five percent of the women in the study
were symptomatic.
Bacterial vaginosis was the most commonly diagnosed re-
productive tract infection, occurring in 38.1% of the study
population. Chlamydial infection and gonorrhea prevalences
were within the expected ranges for this study population.
Five hundred two women had trichomoniasis detected by
wet mount microscopy or culture. Sixty-five percent (n  286)
of all trichomoniasis cases were positive by both wet mount
microscopy and culture, 62 cases (12.3%) were detected by wet
mount microscopy only, and 122 cases (24.3%) were detected
by culture only.
Among the 1,194 study subjects diagnosed with an STD,
22% (n  256) were diagnosed with at least two of gonorrhea,
chlamydial infection, trichomoniasis, or bacterial vaginosis.
Thirty-nine women (3.3%) were diagnosed with three of the
four diseases, and two women (0.2%) were diagnosed with all
four.
Performance of PCR for T. vaginalis using different detec-
tion methods. The development and refinement of the PCR-
based T. vaginalis detection assay included the use of several
methods for detecting amplified products. Initially, PCR prod-
ucts were visualized as ethidium bromide-stained bands of
approximately 300 bp resolved by agarose gel electrophoresis
as previously described by our laboratory and others (8, 11, 28).
A total of 1,513 urine specimens were tested using this method,
1,038 from symptomatic women and 475 from asymptomatic
women. Using the combined reference standard of a positive
wet mount or culture from a vaginal swab, urine-based PCR
with gel detection performed with an overall sensitivity of
66.9% and specificity of 98.3% (Table 2).
In an effort to increase the sensitivity of the PCR assay, we
adopted an ELISA detection method using microtiter plates
coated with an unlabeled oligonucleotide probe specific for an
internal sequence of the amplified product which was gener-
ated with biotin-labeled primers as described in Materials and
Methods. A total of 637 urine specimens were tested using this
method: 451 from symptomatic women and 186 from asymp-
tomatic women. A ROC curve was constructed comparing
urine-based PCR with the unlabeled ELISA to the combined
reference standard from a vaginal swab (Fig. 1). Sensitivity and
specificity for this assay were jointly maximized at an absor-
bance cutoff of 0.500, yielding a sensitivity of 86.4% and
specificity of 86.1% (Table 2).
The imperfect performance of urine PCR with the unlabeled
ELISA prompted further modification of the detection
method. In the third and final version of the urine-based PCR
assay for T. vaginalis, amplified products were labeled with
DIG, the internal probe was biotinylated, and the microtiter
plates for the ELISA were coated with streptavidin as de-
scribed in Materials and Methods. A total of 780 urine speci-
mens were tested using this method (hereafter referred to as T.
vaginalis PCR-ELISA): 549 from symptomatic women and 231
from asymptomatic women. ROC curves for the two ELISA
detection methods are shown in Fig. 1. The absolute absor-
bance value corresponding to the cutoff point with the optimal
TABLE 1. Demographics of study invitees and clinical
characteristics of study participants




African-American 2,449 (81.4) 721 (71.7)
Caucasian 471 (15.7) 106 (10.5)
Latina 52 (1.7) 144 (14.3)
Other 35 (1.2) 7 (0.7)
Not known 2 (0.1) 28 (2.8)
Age (yr)a
18 0 204 (20.3)
18–25 1,587 (52.7) 389 (38.7)
26–35 939 (31.3) 261 (25.9)
36–45 405 (13.5) 108 (10.7)
46 78 (2.6) 19 (1.9)
Mean (SD) 27.1 (7.8) 25.2 (8.3)
Reason for exclusion








STD screening 683 (22.7)
STD contact 377 (12.5)




Genital itch 835 (27.8)
Vaginal irritation 716 (23.9)
Abdominal pain 706 (23.5)
Dysuria 462 (15.4)
Genital ulcer 97 (3.2)
Skin rash 128 (4.3)
Other 566 (18.9)
STDs diagnosedd
C. trachomatis 226 (10.4)
N. gonorrhoeae 174 (6.0)
T. vaginalis 502 (16.7)
Bacterial vaginosise 1,147 (38.1)
Syphilis 9 (0.3)
a Twenty-five women for whom age was unknown were excluded.
b Other reasons for exclusion were improper specimen collection and sched-
uling conflicts.
c Numbers exceed 100% because some women presented to the clinic for
multiple reasons.
d C. trachomatis diagnosed by EIA or LCR; N. gonorrhoeae diagnosed by
culture; T. vaginalis diagnosed by wet mount microscopy and/or culture; bacterial
vaginosis diagnosed by observation of three of the following: white or gray
discharge, fishy odor of discharge, two or more clue cells per microscopic field,
and vaginal pH of 4.5; syphilis diagnosed clinically, and includes all stages of
syphilis as well as cases with stage unknown.
e Bacterial vaginosis is included with classical STDs due to its association with
certain risk factors and because it is most often diagnosed at STD clinics.
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joint sensitivity and specificity was much higher for T. vaginalis
PCR-ELISA (3.0 versus 0.5 for the unlabeled ELISA).
Wet mount microscopy and culture are recognized to have
virtually perfect specificity but imperfect sensitivity for detec-
tion of T. vaginalis. Thus, the observed specificity of T. vaginalis
PCR-ELISA using wet mount or culture as the sole reference
standard is likely underestimated. To examine the degree of
this underestimation, we calculated an adjusted specificity us-
ing the formula of Staquet et al. (27). Assuming that wet mount
or culture has a sensitivity of 70% and that the tests are inde-
pendent, the sensitivity and estimated specificity of T. vaginalis
PCR-ELISA were calculated at different absorbance cutoffs.
The effect of the specificity adjustment on the ROC curve is
shown in Fig. 1. Using an absorbance of 3.0 as the cutoff for the
T. vaginalis PCR-ELISA resulted in an overall sensitivity of
90.8% and an adjusted specificity of 93.4% (Table 3). If the
sensitivity of the reference standard is actually higher than our
assumed value, the specificity of the new test will be slightly
lower; if the sensitivity of wet mount or culture is actually
lower, the specificity of T. vaginalis PCR-ELISA will be higher.
To provide additional insight into the performance of the T.
vaginalis PCR-ELISA, we examined the distribution of absor-
bance values for the assay of urine specimens from subjects
that tested positive or negative using the combined reference
standard from a vaginal swab (Fig. 2). The histograms display
two distinct peaks, with the first at absorbances below 0.3
containing specimens predominantly from women who were
reference standard negative (n  131). The second peak oc-
curred at absorbances greater than 3.0 and contained primarily
specimens from women who were reference standard positive
but also a substantial number of women who were reference
standard negative (n  649). Fewer specimens (3.8% of refer-
ence standard positives and 17.4% of reference standard neg-
atives) yielded absorbances between the two peaks.
Clinical factors affecting T. vaginalis PCR-ELISA perfor-
mance. We compared the performance of T. vaginalis PCR-
ELISA using urine specimens from patients with different clin-
ical characteristics. The test performed with equivalent
sensitivity and specificity in patients with or without an abnor-
mal vaginal discharge; a history of douching; or the presence of
chlamydial infection, gonorrhea, or bacterial vaginosis (data
not shown).
The volume of urine collected and time elapsed since the
previous void were predicted to affect the performance of T.
vaginalis PCR-ELISA. At higher specimen volumes, the ex-
pected concentration of organisms in urine is lower. Likewise,
the more recent the previous void, the lower the expected
concentration of organisms in the test specimen. Although
subjects were instructed to collect only the first 20 ml of first-
void urine, many women were unable to comply with these
instructions. Specimen volumes ranged from 2 to 100 ml, with
a mean volume of 30.8 ml (standard error of the mean, 11.9
ml). The assay was slightly more sensitive with urine specimens
with smaller volumes (20 ml) and when more than 1.5 h had
elapsed since the previous void (Table 4).
DISCUSSION
The urine-based T. vaginalis PCR-ELISA performed with an
overall sensitivity of 90.8% and an adjusted specificity of 93.4%
compared to wet mount and culture from vaginal swabs. De-
TABLE 2. T. vaginalis urine-based PCR performance with specimens from symptomatic and asymptomatic subjects
Subject group
PCR products detected by:
Agarose gel Unlabeled ELISA
n % Sensitivity (95% CI) % Specificity (95% CI) n % Sensitivity (95% CI) % Specificity (95% CI)
Asymptomatic 475 64.3 (44.1, 80.7) 100.0 (97.4, 100.0) 186 80.0 (51.4, 94.7) 82.2 (71.1, 89.8)
Symptomatic 1,038 68.8 (61.8, 75.1) 98.2 (97.0, 99.0) 451 85.9 (76.7, 92.0) 87.5 (83.5, 90.6)
Overall 1,513 66.9 (60.8, 72.5) 98.3 (97.4, 98.9) 637 86.4 (78.6, 91.8) 86.1 (83.2, 88.7)
FIG. 1. ROC analysis of PCR-ELISAs for detection of T. vaginalis
in women’s urine. ROC curves were plotted for the unlabeled ELISA,
the DIG ELISA, and adjusted sensitivity values for the DIG ELISA.
TABLE 3. Urine-based T. vaginalis PCR-ELISA performance with
specimens from symptomatic and asymptomatic subjects






Asymptomatic 231 89.5 (65.5, 98.2) 83.5 (73.9, 90.2) 90.7
Symptomatic 549 91.8 (84.1, 96.2) 87.2 (83.6, 90.0) 95.3
Overall 780 90.8 (84.2, 95.0) 86.1 (83.2, 88.7) 93.4
a Adjusted specificity using the formula of Staquet et al. (27); assumes wet
mount or culture has sensitivity of 70% and specificity of 100% and that tests are
independent.
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tection of amplified target DNA using an ELISA provided an
objective result and improved the sensitivity of the urine based
PCR assay compared to that achieved with gel electrophoresis.
We used two different strategies in the development of T.
vaginalis PCR-ELISA. The unlabeled ELISA relied on hybrid-
ization of PCR products to an unlabeled oligonucleotide probe
coated onto the wells of a microtiter plate. Although the sen-
sitivity of PCR combined with the unlabeled ELISA was im-
proved compared with gel-based detection, the assay specificity
was decreased, and there was unacceptable variation in the
absorbance values of duplicate samples. We attributed the
poor performance of the unlabeled ELISA to the uncontrolled
orientation of the capture probe bound to the microtiter plate
and inconsistent accessibility of the probe for hybridization
with amplified target DNA. Using streptavidin-coated micro-
titer plates to bind the biotin-labeled capture probe in the DIG
ELISA dramatically improved the performance of the assay.
Absorbance values for positive specimens were considerably
higher than those with the unlabeled ELISA, and variation
between duplicate values was minimal.
Other studies using PCR for detection of T. vaginalis in
women’s urine report sensitivities between 64 and 100% and
specificities from 97 to 100% (11, 13, 28). While these studies
are similar in their use of nucleic acid amplification technology,
important differences in urine collection and processing, PCR
primers, and detection methods make direct comparisons be-
tween assays difficult. In a recent comparative study, the prim-
ers used in the current analysis (TVK3 and TVK7) performed
better than other previously reported PCR primer pairs for T.
vaginalis detection in cervicovaginal swab specimens (T. Cru-
citti, E. Van Dyck, S. Abdellati, and M. Laga, Abstr. Int.
Congr. Sex. Transm. Dis., p. 37, 2001). In the T. vaginalis
PCR-ELISA described here, 1 ml of first-void urine was con-
centrated and processed without DNA extraction or purifica-
tion, whereas DNA was extracted from the sediment of up to
50 ml of first-void urine before amplification in other studies
(11, 13, 28).
As with evaluation of any new diagnostic test based on nu-
cleic acid amplification, the selection of a reference standard
was central to the design and outcome of this study. The choice
of vaginal wet mount microscopy and culture as the reference
standard is patient based, reflecting an acceptable reference
standard for trichomoniasis in women. Though T. vaginalis can
be detected on the vaginal epithelium and in urine, results
from both sites are not always concordant. In general, vaginal
specimens are more often positive than urine, whether
trichomonads are detected by wet mount and culture or by
PCR (11, 18). Consequently, diagnosis from urine assay alone
is likely to underestimate the true extent of trichomoniasis in a
given population of women. In a pilot study, we compared
urine culture to wet mount and culture from vaginal swabs for
detection of T. vaginalis in our patient population. Detection
from vaginal specimens was more sensitive than that from
urine; no additional cases of trichomoniasis were identified in
urine cultures beyond those identified in vaginal specimens
(data not shown). Thus, we did not compare the PCR assays to
culture of urine specimens only. Such a comparison would
have overestimated test performance, especially given the pre-
dominance of infections detected by vaginal preparations only.
Although there are clearly limitations to urine compared to
vaginal specimens for T. vaginalis detection in women, the
choice of urine for validation of PCR in this study reflected
several considerations for large-scale population-based studies.
While self-collected vaginal swabs may have performed better
than urine, there are field studies under way and in the plan-
ning stages for which even this minimally invasive sampling is
difficult. Since urine-based amplification tests for gonorrhea
and chlamydia are routinely used, development of a test for
trichomoniasis that would not require an additional specimen
was desirable. In addition, urine can be obtained from women
FIG. 2. Distribution of DIG ELISA absorbance values for T. vagi-
nalis PCR using women’s urine. Histograms show data from women
who were positive (upper panel) or negative (lower panel) by the
reference standard of wet mount and culture from vaginal swabs.
TABLE 4. Effect of specimen collection parameters on T. vaginalis
PCR-ELISA performance







20 186 100.0 (82.2, 100.0) 84.7 (78.0, 89.6) 90.1
20 594 88.9 (81.0, 93.9) 86.6 (83.2, 89.5) 94.6
Time since last
void (h)
1.5 268 91.3 (78.3, 97.2) 86.9 (81.6, 90.9) 94.6
1.5 139 85.7 (66.4, 95.3) 87.4 (79.4, 92.7) 96.2
a Adjusted specificity using the formula of Staquet et al. (27); assumes wet
mount or culture has sensitivity of 70% and specificity of 100% and that tests are
independent.
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and men with uniform specimen collection procedures, making
urine a valuable, if imperfect, specimen.
Comparative studies such as this one, in which an amplifi-
cation test with the potential for high sensitivity is judged
against a less-sensitive culture method, produce a now-familiar
dilemma: how to estimate specificity when it is likely that some
positive results classified as false positives are, in fact, true
positives. Discrepant analysis, which subjects discordant results
to additional testing and reclassification, has been used in
many previous evaluations of new amplification tests. How-
ever, discrepant analysis does not provide valid estimates of
sensitivity or specificity, and its use has been discouraged (5,
14–16). As an alternative to discrepant analysis, we algebra-
ically adjusted specificity estimates for T. vaginalis PCR-ELISA
(27). Using reasonable assumptions for the performance of wet
mount microscopy and culture, this procedure is unlikely to
overestimate the specificity of the new test. We did not adjust
the sensitivity estimate, because we assumed the specificity of
our combined reference standard to be 1.0. However, our
sensitivity may be slightly overestimated due to the potential
for concordant false negatives for PCR and the reference stan-
dard. The estimated sensitivity of the PCR assay is based upon
specimens positive by the combined reference standard. One
would predict that the sensitivity would be lower among
women with trichomoniasis but a negative combined reference
test (16). If these results could be incorporated into the sensi-
tivity estimate, the figure would be lowered slightly.
The observed and adjusted specificities of the T. vaginalis
PCR-ELISA are lower than expected for an amplification test.
This relatively low specificity could potentially result from the
reference test bias noted above (possibly with insufficient ad-
justment algebraically), specimen contamination, or inade-
quate primer specificity. There are two pieces of evidence
suggesting that the observed specificity for the PCR-ELISA is
an underestimate due to reference test bias. Careful examina-
tion of the ROC curve (Fig. 1 [dig ELISA]) reveals that there
is an early deviation of the curve from the vertical axis. The
specificity drops off rapidly, even at very high cutoff values.
This shape of the ROC curve is consistent with the misclassi-
fication of truly positive specimens as false positives. Similarly,
the substantial number of subjects with positive PCR assays at
high absorbances in women with negative wet mounts and
cultures (Fig. 2) suggests that a significant number of women
with trichomoniasis, correctly identified by the PCR, are being
misclassified because of the low sensitivity of the reference
standard. Typically, the probability of a false-positive result is
greater near the chosen cutoff, rather than at more extreme
values. These observations indicate that the specificity may
actually be even higher than the adjusted values.
The relatively uncomplicated urine collection and process-
ing procedures adopted for this study make T. vaginalis PCR-
ELISA an attractive assay for the detection of T. vaginalis in
certain research settings. However, the very features that make
this assay useful from a practical perspective may also explain
its relative insensitivity compared to urine-based nucleic acid
amplification assays for other STD agents. Unlike the gram-
negative bacterial pathogens N. gonorrhoeae and C. trachoma-
tis, the protozoan T. vaginalis lacks a protective outer mem-
brane. Thus, trichomonads are more fragile than most bacteria
and may not survive or remain physically intact during urine
storage and centrifugation before the target DNA can be con-
centrated and further processed. The addition of a preservative
or protectant to urine immediately after collection may stabi-
lize parasites and further improve the performance of this
assay. In a recent report, published after the completion of the
present study, Williams et al. used Fuji culture medium in this
context with promising results (J. A. Williams, N. J. Smith, and
V. Van Der Pol, Abstr. Int. Congr. Sex. Transm. Dis., p. 37,
2001).
PCR inhibitors represent another problem in the develop-
ment of urine-based T. vaginalis detection assays. In experi-
ments using laboratory-grown trichomonads added to urine
from study subjects, approximately 9% of specimens showed
evidence of inhibition (data not shown). Inhibition was abol-
ished when smaller template volumes were used for PCR am-
plification or when preparations were extracted with phenol-
chloroform and precipitated with sodium acetate; however, we
did not systematically assess inhibitory activity in urines
throughout the study. The addition of an internal amplification
control and interpretation guidelines for inhibitory specimens
should greatly improve the performance of urine-based ampli-
fication assays for detection of T. vaginalis.
Despite the high prevalence of T. vaginalis infection world-
wide (20, 21, 23) and the association of trichomoniasis with
adverse pregnancy outcomes (3, 6, 17) and more recently with
increased HIV transmission (2, 10), efforts to improve diagno-
sis of this STD have not kept pace with diagnostic develop-
ments for gonorrhea and chlamydia. Particularly for large-
scale, population-based studies conducted without clinic or
immediate laboratory access, reliable and sensitive urine-based
testing for T. vaginalis is necessary. The current study was
specifically designed to fulfill this need. Accordingly, urine
specimen collection, storage, and transport conditions imple-
mented in this study were kept simple so that these conditions
could be reproduced in field studies. Urine specimen process-
ing was likewise simplified using sample volumes and commer-
cially available kit reagents optimized for batch handling in
typical laboratory microcentrifuges. PCR combined with
ELISA for detection of T. vaginalis in women’s urine per-
formed well compared to wet mount microscopy and culture
from vaginal swabs. Further improvements in the assay and
validation of the test using specimens from men are currently
under way. The T. vaginalis PCR-ELISA should be useful for
the detection of this under-studied organism in settings where
microscopy and culture are not practical.
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